US FDA flags blindness risk from GLP-1 drugs: What patients should know
The US regulator has called for new eye-related warnings on GLP-1 drug labels, but Indian safety data remains limited
Attributed summary
The US regulator has called for new eye-related warnings on GLP-1 drug labels, but Indian safety data remains limited
Read the original report — Business Standard
Storywire publishes attributed summaries for discoverability. Full reporting remains with the original publisher — we do not republish restricted full text.
